Searchable abstracts of presentations at key conferences in endocrinology

ea0011p482 | Endocrine tumours and neoplasia | ECE2006

48 h appears as sufficient duration of fasting in the diagnosis of insulinoma – a single centre experience with 23 cases

Quinkler M , Strehlow F , Biering H , Pirlich M , Gerl H , Strasburger CJ , Ventz M

Insulinoma causes fasting hypoglycemia due to inappropriate insulin secretion. The diagnosis of insulinoma is based on Whipple’s triad (1. symptoms precipitated by fasting with 2. associated blood sugars of 50 mg/dl or less and 3. relief of symptoms by glucose administration) during a supervised 72 h fasting test. After introducing reliable assays for measurement of insulin and proinsulin, there is an ongoing debate whether a 48 h fasting test is sufficient for diagnosis ...

ea0014oc10.2 | Obesity & metabolism | ECE2007

11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) mRNA expression in liver of patients with non-alcoholic steatohepatitis

Konopelska Sarah , Kienitz Tina , Pirlich Matthias , Bauditz Jürgen , Stewart Paul M. , Lochs Herbert , Strasburger Christian J. , Quinkler Marcus

Background: Non-alcoholic fatty liver disease (NAFLD) is recognized as common liver disorder that represents the hepatic manifestation of the metabolic syndrome including visceral obesity, type 2 diabetes, insulin resistance and hyperlipidemia. Non-alcoholic steatohepatitis (NASH) is the progressive form of liver injury with the risk for progressive fibrosis, cirrhosis and end-stage liver disease. The pathophysiology that leads to NAFLD and NASH is not well understood. We hypo...

ea0013p171 | Diabetes, metabolism and cardiovascular | SFEBES2007

Abdominal obesity is associated with a decreased hepatic mRNA expression of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) in patients with non-alcoholic steatohepatitis (NASH)

Konopelska Sarah , Kienitz Tina , Pirlich Matthias , Bauditz Juergen , Stewart Paul M , Hughes Beverly , Lochs Herbert , Strasburger Christian J , Quinkler Marcus

Background: Non-alcoholic fatty liver disease (NAFLD) is recognized as common liver disorder that represents the hepatic manifestation of the metabolic syndrome including visceral obesity, type 2 diabetes, insulin resistance and hyperlipidemia. Non-alcoholic steatohepatitis (NASH) is the progressive form of liver injury with the risk for progressive fibrosis, cirrhosis and end-stage liver disease. The pathophysiology that leads to NAFLD and NASH is not well understood. We hypo...